EP2812355A4 - COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS - Google Patents

COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS

Info

Publication number
EP2812355A4
EP2812355A4 EP13746304.8A EP13746304A EP2812355A4 EP 2812355 A4 EP2812355 A4 EP 2812355A4 EP 13746304 A EP13746304 A EP 13746304A EP 2812355 A4 EP2812355 A4 EP 2812355A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
csf1r inhibitors
csf1r
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13746304.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2812355A1 (en
Inventor
Xiaolei Ma
Yongmei Chen
Scott Stawicki
Yan Wu
Flavius Martin
wei yu Lin
Melissa A Starovasnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP2812355A1 publication Critical patent/EP2812355A1/en
Publication of EP2812355A4 publication Critical patent/EP2812355A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13746304.8A 2012-02-06 2013-02-06 COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS Withdrawn EP2812355A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595658P 2012-02-06 2012-02-06
US201261680674P 2012-08-07 2012-08-07
PCT/US2013/024998 WO2013119716A1 (en) 2012-02-06 2013-02-06 Compositions and methods for using csf1r inhibitors

Publications (2)

Publication Number Publication Date
EP2812355A1 EP2812355A1 (en) 2014-12-17
EP2812355A4 true EP2812355A4 (en) 2016-03-02

Family

ID=48947977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13746304.8A Withdrawn EP2812355A4 (en) 2012-02-06 2013-02-06 COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS

Country Status (9)

Country Link
EP (1) EP2812355A4 (enrdf_load_stackoverflow)
JP (2) JP6416630B2 (enrdf_load_stackoverflow)
KR (1) KR20140127855A (enrdf_load_stackoverflow)
CN (1) CN104093740B (enrdf_load_stackoverflow)
BR (1) BR112014018961A8 (enrdf_load_stackoverflow)
CA (1) CA2861122A1 (enrdf_load_stackoverflow)
MX (1) MX2014008961A (enrdf_load_stackoverflow)
RU (1) RU2014136332A (enrdf_load_stackoverflow)
WO (1) WO2013119716A1 (enrdf_load_stackoverflow)

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
KR20140113683A (ko) 2011-12-15 2014-09-24 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SMT201800643T1 (it) 2013-12-24 2019-01-11 Bristol Myers Squibb Co Composti triciclici come agenti anticancro
LT3151921T (lt) 2014-06-06 2019-12-10 Bristol Myers Squibb Co Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas
MX2016015610A (es) 2014-06-06 2017-07-13 Flexus Biosciences Inc Agentes inmunorreguladores.
MA40406A (fr) * 2014-07-28 2016-02-04 Nogra Pharma Ltd Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
MX383868B (es) 2014-11-21 2025-03-14 Bristol Myers Squibb Co Anticuerpos contra cd73 y sus usos.
JP6827928B2 (ja) * 2014-12-19 2021-02-10 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
KR102644115B1 (ko) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Tigit에 대한 항체
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
BR112017017135A2 (pt) 2015-03-02 2018-04-03 Rigel Pharmaceuticals, Inc. inibidores de tgf-beta
EP3277672A1 (en) 2015-04-03 2018-02-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US10591465B2 (en) 2015-05-12 2020-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016189045A1 (en) * 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
JP2018526344A (ja) 2015-07-28 2018-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
EP3353198B1 (en) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
SG11201803817PA (en) 2015-11-19 2018-06-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
EP3452452A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
WO2017192811A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190003686A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
JP2019516687A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
UY37325A (es) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
KR20190040990A (ko) 2016-08-26 2019-04-19 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
EP3503891A1 (en) 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
KR102611446B1 (ko) 2017-01-20 2023-12-06 아르커스 바이오사이언시즈 인코포레이티드 암-관련 장애의 치료를 위한 아졸로피리미딘
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI778050B (zh) 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7189155B2 (ja) 2017-05-17 2022-12-13 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体
KR102651568B1 (ko) 2017-05-19 2024-03-25 신닥스 파마슈티컬스, 인크. 조합 요법
EA202090119A1 (ru) 2017-06-30 2020-04-21 Бристол-Маерс Сквибб Компани Аморфные и кристаллические формы ido-ингибиторов
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
CN111163766A (zh) 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
EP3676278B1 (en) 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7212683B2 (ja) 2017-10-10 2023-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111406063B (zh) 2017-10-16 2023-09-15 百时美施贵宝公司 作为抗癌剂的环二核苷酸
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR102813744B1 (ko) 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019147982A1 (en) 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
JP7229257B2 (ja) 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
WO2019169291A1 (en) * 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
AU2019230001A1 (en) * 2018-03-05 2020-09-24 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of CSF1R
EP3761992A4 (en) 2018-03-05 2021-11-24 Arcus Biosciences, Inc. ARGINASE INHIBITORS
KR20200130362A (ko) 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN112154153B (zh) 2018-03-28 2025-05-23 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
KR20200142542A (ko) 2018-04-12 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
PL3814348T3 (pl) 2018-06-27 2023-09-11 Bristol-Myers Squibb Company Podstawione związki naftyrydynonu przydatne jako aktywatory komórek t
MX2020013373A (es) 2018-06-27 2021-03-09 Bristol Myers Squibb Co Compuestos de naftiridinona utiles como activadores de celulas t.
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
CN119390840A (zh) 2018-07-09 2025-02-07 戊瑞治疗有限公司 结合到ilt4的抗体
KR20210031722A (ko) 2018-07-11 2021-03-22 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
US11993584B2 (en) 2018-07-18 2024-05-28 Arcus Biosciences, Inc. Solid forms of an azolopyrimidine compound
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
EP3880708A1 (en) 2018-11-16 2021-09-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
JP7461350B2 (ja) 2018-11-16 2024-04-03 アーカス バイオサイエンシーズ インコーポレイテッド Ａｒｇ１及び／又はａｒｇ２の阻害剤
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020206424A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
CN113795267A (zh) 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
CN113874397A (zh) 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN114729043A (zh) 2019-09-19 2022-07-08 百时美施贵宝公司 在酸性pH下结合至VISTA的抗体
EP4061812A1 (en) 2019-11-19 2022-09-28 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein
CN115279764A (zh) 2019-11-26 2022-11-01 医肯纳肿瘤学公司 多晶型咔唑衍生物及其用途
WO2021108288A1 (en) 2019-11-26 2021-06-03 Bristol-Myers Squibb Company Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2020407200A1 (en) 2019-12-17 2022-07-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
US20230061608A1 (en) 2019-12-23 2023-03-02 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
US20230118629A1 (en) 2019-12-23 2023-04-20 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
CN114846007B (zh) 2019-12-23 2024-11-22 百时美施贵宝公司 可用作t细胞激活剂的经取代的喹唑啉基化合物
WO2021133752A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as t cell activators
TWI867138B (zh) 2020-01-06 2024-12-21 美商高誠生物醫藥股份有限公司 抗tnfr2抗體及其用途
MX2022008421A (es) 2020-01-07 2022-09-23 Hifibio Hk Ltd Anticuerpo anti-galectina-9 y usos del mismo.
BR112022017727A2 (pt) 2020-03-03 2022-11-16 Pic Therapeutics Inc Inibidores de eif4e e usos dos mesmos
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
MX2022011534A (es) 2020-03-19 2022-10-13 Arcus Biosciences Inc Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
AR121898A1 (es) 2020-04-30 2022-07-20 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN115698068A (zh) 2020-06-02 2023-02-03 艾库斯生物科学有限公司 抗tigit抗体
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
AU2021292195A1 (en) 2020-06-17 2023-01-05 Arcus Biosciences, Inc. Crystalline forms of a CD73 inhibitor and uses thereof
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
PH12023550237A1 (en) 2020-07-30 2024-04-29 Kymera Therapeutics Inc Methods of treating mutant lymphomas
IL300537A (en) 2020-08-10 2023-04-01 Gv20 Therapeutics Llc Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
CN117015531A (zh) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 Tead抑制剂及其用途
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CA3206499A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
EP4291197A4 (en) 2021-02-15 2024-12-25 Kymera Therapeutics, Inc. IRAK4 DEGRADING AGENTS AND THEIR USES
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20230167067A (ko) 2021-04-05 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
TWI867287B (zh) 2021-04-06 2024-12-21 美商必治妥美雅史谷比公司 經吡啶基取代之側氧基異吲哚啉化合物
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
JP2024514879A (ja) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
MX2023013563A (es) 2021-05-17 2023-11-29 Nogra Pharma Ltd Agentes antisentido de il-34 y metodos de uso de los mismos.
TW202313603A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
CN117295741A (zh) 2021-05-21 2023-12-26 艾库斯生物科学有限公司 Axl化合物
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4392422A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US12071411B2 (en) 2021-10-29 2024-08-27 Arcus Biosciences, Inc. Inhibitors of HIF-2α and methods of use thereof
CN118525032A (zh) * 2021-10-29 2024-08-20 伊莱利利公司 靶向白细胞介素34的化合物和方法
JP7622019B2 (ja) 2021-10-29 2025-01-27 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
KR20240105403A (ko) * 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
KR20240110592A (ko) 2021-10-29 2024-07-15 카이메라 쎄라퓨틱스 인코포레이티드 Irak4 분해제 및 이의 합성
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2025503312A (ja) 2022-02-01 2025-01-30 アルビナス・オペレーションズ・インコーポレイテッド Ｄｇｋ標的化化合物およびその使用
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
KR20250006959A (ko) 2022-05-02 2025-01-13 아르커스 바이오사이언시즈 인코포레이티드 항-tigit 항체 및 이의 용도
EP4532470A1 (en) 2022-05-25 2025-04-09 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
TW202415650A (zh) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 芳基-三唑基及相關gpr84拮抗劑及其用途
AU2023317740A1 (en) 2022-08-02 2025-03-13 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
CN119654312A (zh) 2022-08-08 2025-03-18 百时美施贵宝公司 用作t细胞活化剂的取代的四唑基化合物
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
TW202500139A (zh) 2023-05-08 2025-01-01 美商必治妥美雅史谷比公司 經取代之苯基㗁唑酮化合物
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
WO2025049840A1 (en) 2023-09-02 2025-03-06 Bristol-Myers Squibb Company Substituted phenyl oxooxazolyl piperidine dione compounds
US20250084056A1 (en) 2023-09-13 2025-03-13 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
WO2025096539A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US12176075B1 (en) * 2023-11-14 2024-12-24 United Arab Emirates University Method of matching conformers of different molecules
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112245A1 (en) * 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112245A1 (en) * 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2011140249A2 (en) * 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DROIN NATHALIE ET AL: "Editorial: CSF1R, CSF-1, and IL-34, a menage a trois conserved across vertebrates", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 87, no. 5, 1 May 2010 (2010-05-01), pages 745 - 747, XP009138538, ISSN: 0741-5400, DOI: 10.1189/JLB.1209780 *
HAISHAN LIN ET AL: "Discovery of a cytokine and its receptor by functional screening of the extracellular proteome", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 320, no. 5877, 9 May 2008 (2008-05-09), pages 807 - 811, XP002638423, ISSN: 1095-9203, DOI: 10.1126/SCIENCE.1154370 *
See also references of WO2013119716A1 *
T CHIHARA ET AL: "IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation", CELL DEATH AND DIFFERENTIATION, vol. 17, no. 12, 1 December 2010 (2010-12-01), pages 1917 - 1927, XP055036155, ISSN: 1350-9047, DOI: 10.1038/cdd.2010.60 *

Also Published As

Publication number Publication date
BR112014018961A2 (enrdf_load_stackoverflow) 2017-06-20
MX2014008961A (es) 2014-10-14
WO2013119716A1 (en) 2013-08-15
CN104093740A (zh) 2014-10-08
JP2015510510A (ja) 2015-04-09
CA2861122A1 (en) 2013-08-15
BR112014018961A8 (pt) 2017-07-11
CN104093740B (zh) 2018-01-09
KR20140127855A (ko) 2014-11-04
JP6416630B2 (ja) 2018-10-31
WO2013119716A8 (en) 2014-08-07
JP2017200482A (ja) 2017-11-09
HK1202879A1 (en) 2015-10-09
RU2014136332A (ru) 2016-03-27
EP2812355A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
EP2812355A4 (en) COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
EP2773651A4 (en) ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND APPLICATION METHOD THEREFOR
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2903637A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP2579831A4 (en) DONATION AND APPLICATION PROCEDURE
EP2920319A4 (en) LOCAL ENZYMES AND METHODS OF USE
EP2673381A4 (en) BIOSONDES AND METHOD FOR THEIR USE
EP2667889A4 (en) WNT COMPOSITIONS AND USE METHOD THEREFOR
EP2861539A4 (en) Novel BioCATALYZER COMPOSITIONS AND METHODS OF USE
EP2619184A4 (en) DEUBIQUITINASE INHIBITORS AND METHOD FOR THEIR USE
EP2844292A4 (en) ST2L ANTAGONISTS AND METHOD OF USE
EP2938189A4 (en) CONTROLLED RELEASED COMPOSITIONS AND USAGE PROCEDURES
EP2836218A4 (en) PROBIOTIC COMPOSITIONS AND METHODS OF USE
EP2838468A4 (en) INTRAORAL LIGHT THERAPY DEVICES AND METHOD FOR THEIR USE
EP2914575A4 (en) PLASMINOGEN ACTIVATOR 1 HEMMER AND METHOD FOR USE THEREOF
EP2964235A4 (en) ANTIMICROBIAL ANTIBIOFILM COMPOSITIONS AND METHOD FOR USE THEREOF
EP2658580A4 (en) ARGINE STARTER AND USE METHOD
EP2833879A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP2895181A4 (en) TOPICAL COMPOSITIONS AND METHODS OF USE
EP2544679A4 (en) PDE10-HEMMER AND CORRESPONDING COMPOSITIONS AND METHODS
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
EP2866854A4 (en) METHOD OF USE OF POLYMERS
EP2701512A4 (en) ALDOSTERONSYNTHASEHEMMER
EP2776437A4 (en) Modulators of opioid receptors and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/24 20060101AFI20151113BHEP

Ipc: A61K 39/395 20060101ALI20151113BHEP

Ipc: A61P 19/02 20060101ALI20151113BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20160122BHEP

Ipc: A61P 19/02 20060101ALI20160122BHEP

Ipc: C07K 16/24 20060101AFI20160122BHEP

R17P Request for examination filed (corrected)

Effective date: 20140908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181027